Methohexital
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Black Box Warning
WARNING
See full prescribing information for complete Boxed Warning.
Brevital should be used only in hospital or ambulatory care settings that provide for continuous monitoring of respiratory (e.g. pulse oximetry) and cardiac function. Immediate availability of resuscitative drugs and age- and size-appropriate equipment for bag/valve/mask ventilation and intubation and personnel trained in their use and skilled in airway management should be assured. For deeply sedated patients, a designated individual other than the practitioner performing the procedure should be present to continuously monitor the patient. (See WARNINGS)
|
Overview
Methohexital is a general anesthetic that is FDA approved for the {{{indicationType}}} of anesthesia. There is a Black Box Warning for this drug as shown here. Common adverse reactions include cardiovascular: hypotension, dermatologic: injection site pain, musculoskeletal: spasmodic movement, respiratory: cough, hiccoughs, laryngeal spasm.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
- Anesthesia: induction, 1 to 1.5 mg/kg (50 to 120 mg, mean 70 mg) IV administered at a rate of 1 mL every 5 seconds (1% solution), which usually provides anesthesia for 5 to 7 minutes; gaseous anesthetics and skeletal muscle relaxants may be administered concomitantly [2]
- Anesthesia: maintenance, intermittent IV injections of 20 to 40 mg (2 to 4 mL of a 1% solution) as required, usually every 4 to 7 minutes OR by continuous IV drip of 3 mL/min (0.2% solution); individualize flow rate for each patient; for longer surgical procedures, gradual reduction in the administration rate is recommended [2]
- Procedural sedation: 0.75 to 1 mg/kg IV; can be re-dosed 0.5 mg/kg every 2-5 min as needed
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
- Procedural sedation.
Non–Guideline-Supported Use
There is limited information about Off-Label Non–Guideline-Supported Use of Methohexital in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
- Anesthesia: (older than 1 month) 6.6 to 10 mg/kg IM (5% solution) OR 25 mg/kg RECTALLY (1% solution).
- Procedural sedation: 25 mg/kg RECTALLY as 1% solution.
- Procedural sedation: 0.5 to 1 mg/kg IV.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
- Procedural sedation
Non–Guideline-Supported Use
There is limited information about Off-Label Non–Guideline-Supported Use of Methohexital in pediatric patients.
Contraindications
There is limited information regarding Methohexital Contraindications in the drug label.
Warnings
WARNING
See full prescribing information for complete Boxed Warning.
Brevital should be used only in hospital or ambulatory care settings that provide for continuous monitoring of respiratory (e.g. pulse oximetry) and cardiac function. Immediate availability of resuscitative drugs and age- and size-appropriate equipment for bag/valve/mask ventilation and intubation and personnel trained in their use and skilled in airway management should be assured. For deeply sedated patients, a designated individual other than the practitioner performing the procedure should be present to continuously monitor the patient. (See WARNINGS)
|
There is limited information regarding Methohexital Warnings' in the drug label.
Adverse Reactions
Clinical Trials Experience
There is limited information regarding Methohexital Clinical Trials Experience in the drug label.
Postmarketing Experience
There is limited information regarding Methohexital Postmarketing Experience in the drug label.
Drug Interactions
There is limited information regarding Methohexital Drug Interactions in the drug label.
Use in Specific Populations
Pregnancy
Pregnancy Category (FDA):
There is no FDA guidance on usage of Methohexital in women who are pregnant.
Pregnancy Category (AUS):
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Methohexital in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Methohexital during labor and delivery.
Nursing Mothers
There is no FDA guidance on the use of Methohexital in women who are nursing.
Pediatric Use
There is no FDA guidance on the use of Methohexital in pediatric settings.
Geriatic Use
There is no FDA guidance on the use of Methohexital in geriatric settings.
Gender
There is no FDA guidance on the use of Methohexital with respect to specific gender populations.
Race
There is no FDA guidance on the use of Methohexital with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Methohexital in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Methohexital in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Methohexital in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Methohexital in patients who are immunocompromised.
Administration and Monitoring
Administration
There is limited information regarding Methohexital Administration in the drug label.
Monitoring
There is limited information regarding Methohexital Monitoring in the drug label.
IV Compatibility
There is limited information regarding the compatibility of Methohexital and IV administrations.
Overdosage
There is limited information regarding Methohexital overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.
Pharmacology
There is limited information regarding Methohexital Pharmacology in the drug label.
Mechanism of Action
There is limited information regarding Methohexital Mechanism of Action in the drug label.
Structure
There is limited information regarding Methohexital Structure in the drug label.
Pharmacodynamics
There is limited information regarding Methohexital Pharmacodynamics in the drug label.
Pharmacokinetics
There is limited information regarding Methohexital Pharmacokinetics in the drug label.
Nonclinical Toxicology
There is limited information regarding Methohexital Nonclinical Toxicology in the drug label.
Clinical Studies
There is limited information regarding Methohexital Clinical Studies in the drug label.
How Supplied
There is limited information regarding Methohexital How Supplied in the drug label.
Storage
There is limited information regarding Methohexital Storage in the drug label.
Images
Drug Images
{{#ask: Page Name::Methohexital |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Methohexital |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
There is limited information regarding Methohexital Patient Counseling Information in the drug label.
Precautions with Alcohol
Alcohol-Methohexital interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
There is limited information regarding Methohexital Brand Names in the drug label.
Look-Alike Drug Names
There is limited information regarding Methohexital Look-Alike Drug Names in the drug label.
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.